Table 2.
Recent clinical trials with ketamine in treatment-resistant depression (2014 and later).
| Phase | Sponsor | Identifier | Primary outcome | Time frame | N a | Results or status |
|---|---|---|---|---|---|---|
| III | VA Office of R&D (USA) | NCT02556606 | Time to relapse | 4 W | 72 | March 2020b |
| II/III | University of Ottawa (Canada) | NCT01945047 | Safety & HDRSi | 2 W | 63 | December 2015b |
| II | Janssen R&D (USA) | Singh et al, 2016 [38] | MADRSj | 15 D | 68 | KET = −17.7d, c, PL = −3.1 |
| Massachusetts General Hospital (USA) | NCT01920555 | HDRSi | 24 H | 100 | January 2016b | |
| Veteran’s Affairs Office R&D (USA) | NCT02360280 | MADRSj | 13 D | 56 | January 2018b | |
| Paul J. Lamothee (Mexico) | NCT01868802 | HDRSi | 1–7 D | 60 | May 2016b | |
| Magdeburg Universityg (Germany) | EU 2010–023414-31 | HDRSi | 24 H | 40 | NC | |
| University of Minnesotaf (USA) | NCT02078817 | CGI | 1 W | 20 | April 2016b | |
| Mayo Clinic (USA) | NCT02094898 | MADRSj | 8Wh | 30 | June 2016b |
a
Enrolment (final or estimated).
b
Primary completion date (past or estimated).
c
Intravenous ketamine at 0.5 mg/kg, thrice-weekly.
d
Statistically significant.
e
American British Cowdray Medical Center.
f
Clinical and Translational Science Institute.
g
Department of Psychiatry, School of Medicine.
h
Maintenance treatment (4 weeks) + follow up after treatment ends for four weeks.
i
Hamilton Depression Rating Scale.
j
Montgomery–Asberg Depression Rating Scale.
CGI: Clinical Global Impression; D: days; EU: EudraCT number; H: hours; KET: ketamine; NC: not communicated; PL: placebo; R&D: research development; W: weeks.